2006, generic clopidogrel was briefly marketed by Apotex, a Canadian generic pharmaceutical company before a court order halted further production until resolution of a patent infringement case brought by Bristol-Myers Squibb.[36] The court ruled that Bristol-Myers Squibb's patent was valid and provided protection until November 2011.[37] The FDA extended the patent protection of clopidogrel by six months, giving exclusivity that would expire on May 17, 2012.[38] The FDA approved generic versions of Plavix on May 17, 2012.[39]
In June 2009, the European Medicines Agency gave authorisation to six generic versions of clopidogrel bisulfate, and the drug is now available in several European countries, including the United Kingdom.[40]
Generic clopidogrel is produced by several pharmaceutical companies in India and elsewhere, and often sold under its INN. It is marketed by Cipla under the trade name Clopivas, by Sun Pharmaceuticals as Clopilet, by Ranbaxy Laboratories as Ceruvin, as Clavix by Intas Pharmaceuticals, and as Deplatt by Torrent Pharmaceuticals. In India, it is sold as Clopivas AP by Cipla, Clopigrel A by USV, and Clopitab A by Lupin(mixed with aspirin).[citation needed]
Generic clopidogrel is produced in Slovenia (European Union) under the trade names Zyllt, Kardogrel and Clopidogrel Krka by Krka d.d., Novo Mesto.[41]
Another generic clopidogrel is produced for Julphar brand (Gulf Pharmaceutical Industries) UAE (GCC) as Lavigard, and by EGIS Pharmaceuticals PLC, Budapest, Hungary, as Clopidogrel.
| 